AbbVie Inc. $ABBV Shares Sold by Exchange Traded Concepts LLC

Exchange Traded Concepts LLC lessened its position in shares of AbbVie Inc. (NYSE:ABBV) by 45.6% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 41,612 shares of the company’s stock after selling 34,825 shares during the period. Exchange Traded Concepts LLC’s holdings in AbbVie were worth $9,635,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of ABBV. Marshall & Sullivan Inc. WA acquired a new stake in AbbVie in the second quarter valued at $25,000. Evolution Wealth Management Inc. acquired a new stake in shares of AbbVie during the 2nd quarter worth about $26,000. TD Capital Management LLC lifted its stake in AbbVie by 82.9% during the first quarter. TD Capital Management LLC now owns 128 shares of the company’s stock worth $27,000 after purchasing an additional 58 shares during the last quarter. Spurstone Advisory Services LLC acquired a new position in AbbVie in the second quarter valued at approximately $28,000. Finally, Financial Gravity Companies Inc. purchased a new position in AbbVie in the second quarter valued at approximately $36,000. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Price Performance

AbbVie stock opened at $228.74 on Wednesday. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.72 and a quick ratio of 0.60. The business has a 50 day simple moving average of $226.57 and a 200-day simple moving average of $211.87. AbbVie Inc. has a 12 month low of $164.39 and a 12 month high of $244.81. The stock has a market capitalization of $404.28 billion, a PE ratio of 173.29, a price-to-earnings-growth ratio of 1.29 and a beta of 0.36.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.09. The company had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. AbbVie’s revenue was up 9.1% compared to the same quarter last year. During the same period in the previous year, the company posted $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Equities analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be issued a dividend of $1.73 per share. This is an increase from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a yield of 3.0%. The ex-dividend date of this dividend is Friday, January 16th. AbbVie’s dividend payout ratio is currently 496.97%.

Wall Street Analyst Weigh In

ABBV has been the subject of several research analyst reports. Erste Group Bank cut shares of AbbVie from a “buy” rating to a “hold” rating in a report on Tuesday, October 14th. Citigroup dropped their price objective on AbbVie from $240.00 to $235.00 and set a “neutral” rating on the stock in a report on Monday, November 3rd. Wall Street Zen raised AbbVie from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 13th. Evercore ISI lifted their price target on AbbVie from $207.00 to $222.00 and gave the stock an “outperform” rating in a research report on Monday, September 22nd. Finally, UBS Group increased their price objective on AbbVie from $195.00 to $220.00 and gave the company a “neutral” rating in a report on Friday, November 7th. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have issued a Hold rating to the company’s stock. According to MarketBeat, AbbVie has an average rating of “Moderate Buy” and a consensus price target of $245.84.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.